Founded with a mission to revolutionize mental health treatment, Gilgamesh Pharmaceuticals is a clinical stage biotechnology company focused on developing innovative new chemical entities (NCEs). Leveraging a unique combination of medicinal chemistry, intellectual property strategy, neuroscience, and drug development expertise, the company aims to create rapid-acting and long-lasting therapies that target the root causes of neurological diseases. Their market focus is on precision psychiatric therapies that are orally bioavailable and move beyond symptom management.

Notable for its experienced team with a track record of successful biotech exits and inventions, Gilgamesh Pharmaceuticals has garnered attention from key investors in the biotech sector. The company has made significant strides in mental health science, utilizing an AI-powered discovery and translational platform to accelerate drug development. Their impact lies in the potential to offer safer, more effective treatments for mental health conditions, setting new standards in the industry.